Despite the presence of the KIT D816V mutation not serving as an indicator of SM in the AML1::ETO + AML subgroup (10), according to the two retrospective studies cited, the incidence of AML1::ETO + AML cases with KIT mutations concurrent with mastocytosis has been underestimated. This evidence concerns the gene KIT and mastocytosis.